Acadia Pharmaceuticals Q3 net income falls 25% to $53.52 million

By Public Technologies21:27 (UTC), 4 November 2026 Updated

Acadia Pharmaceuticals’ third-quarter 2026 net income fell 25% year-over-year to $53.52 million.
Total revenues rose 23% year-over-year to $342.29 million.
Research and development expenses dropped 13% to $76.28 million, with 2026 guidance lowered to $325 million–$340 million.
DAYBU launched in Germany in early October following European Commission approval for treating Rett syndrome.
Two Phase 2 readouts are expected in 2027: ACP-211 in major depressive disorder and remlifanserin in Lewy body dementia psychosis.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ACADIA Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202611041605BIZWIRE_USPR_____20261104_BW772757) on November 04, 2026, and is solely responsible for the information contained therein.